AnaptysBio abandons eczema drug after trial failures; shares nosedive
Biotechnology company AnaptysBio, Inc., specializing in innovative autoimmune disease therapies, announced it will halt development of its atopic dermatitis treatment, ANB032, after the drug failed ... Read More
Taro Pharmaceutical ends licensing agreement with NovaBiotics over Novexatin failure
Taro Pharmaceutical Industries has terminated its licensing agreement with Scottish biotech company NovaBiotics concerning the Novexatin drug after disappointing clinical trial results. The decision follows ... Read More